IOL Chemicals & Pharmaceuticals Ltd

IOL Chemicals Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

IOL Chemicals & Pharmaceuticals Ltd

₹ 92.8 -0.64%
31 Oct 11:53 a.m.
iolcp.com BSE: 524164 NSE: IOLCP
About

IOL Chemicals & Pharmaceuticals Ltd is a leading pharmaceutical (APIs) company and is a significant player in the specialty chemicals space. It serves the domestic and export market.[1]

It is the largest player of Ibuprofen (pain killer) globally with a world market share of 35%.[2]

Key Points

Business Segments

Website BSE NSE
  • Market Cap ₹ 2,722 Cr.
  • Current Price ₹ 92.8
  • High / Low ₹ 127 / 57.5
  • Stock P/E 25.8
  • Book Value ₹ 57.5
  • Dividend Yield 0.86 %
  • ROCE 8.86 %
  • ROE 6.13 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 20.6%

Cons

  • The company has delivered a poor sales growth of 1.88% over past five years.
  • Company has a low return on equity of 8.09% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare BSE SmallCap BSE Allcap

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
565 541 523 587 563 545 520 504 502 526 523 528 552
509 510 480 491 490 481 476 454 452 484 476 465 490
Operating Profit 56 32 43 96 73 64 44 50 51 42 47 63 62
OPM % 10% 6% 8% 16% 13% 12% 9% 10% 10% 8% 9% 12% 11%
5 5 7 9 7 7 8 8 7 6 4 5 7
Interest 3 4 5 5 4 4 4 3 2 4 4 4 4
Depreciation 11 11 12 12 14 16 16 16 17 18 19 19 20
Profit before tax 47 22 33 88 62 51 32 38 39 26 28 45 46
Tax % 25% 28% 27% 25% 25% 26% 28% 25% 24% 26% 26% 30% 25%
35 16 24 65 46 38 23 28 30 19 21 32 34
EPS in Rs 1.19 0.53 0.82 2.22 1.57 1.29 0.79 0.96 1.01 0.65 0.70 1.08 1.16
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
564 385 580 711 983 1,685 1,894 1,967 2,184 2,217 2,133 2,079 2,129
468 373 529 608 863 1,276 1,321 1,375 1,927 1,990 1,901 1,877 1,915
Operating Profit 96 11 51 102 120 410 574 592 257 227 232 202 214
OPM % 17% 3% 9% 14% 12% 24% 30% 30% 12% 10% 11% 10% 10%
1 1 1 1 6 10 16 24 17 25 30 22 22
Interest 60 59 61 68 64 51 21 6 8 16 16 15 17
Depreciation 32 29 30 30 30 32 36 39 43 46 63 72 75
Profit before tax 5 -75 -39 6 31 336 533 571 223 189 183 138 144
Tax % 35% -12% 4% 21% 12% 30% 32% 22% 26% 26% 26% 27%
3 -67 -40 5 28 237 361 445 166 140 135 101 105
EPS in Rs 0.23 -2.80 -1.42 0.17 0.99 8.32 12.70 15.15 5.64 4.77 4.61 3.44 3.59
Dividend Payout % 0% 0% 0% 0% 0% 0% 5% 8% 14% 17% 22% 23%
Compounded Sales Growth
10 Years: 18%
5 Years: 2%
3 Years: -2%
TTM: 3%
Compounded Profit Growth
10 Years: 13%
5 Years: -22%
3 Years: -17%
TTM: -11%
Stock Price CAGR
10 Years: 19%
5 Years: -7%
3 Years: 9%
1 Year: 16%
Return on Equity
10 Years: 18%
5 Years: 14%
3 Years: 8%
Last Year: 6%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 29 48 56 56 56 57 57 59 59 59 59 59
Reserves 160 160 129 132 160 417 757 1,202 1,332 1,448 1,553 1,629
377 400 453 447 422 284 59 3 44 80 33 117
175 94 135 182 214 184 297 347 526 434 600 577
Total Liabilities 741 702 772 817 852 942 1,170 1,610 1,960 2,021 2,244 2,382
411 403 400 374 406 412 469 512 561 751 933 1,170
CWIP 33 4 4 21 7 27 19 48 105 90 101 22
Investments 0 0 0 0 0 0 0 1 2 20 21 21
297 295 369 422 439 503 682 1,048 1,292 1,159 1,190 1,168
Total Assets 741 702 772 817 852 942 1,170 1,610 1,960 2,021 2,244 2,382

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
78 -47 18 83 120 273 471 380 91 123 290 179
-12 -5 -27 -23 -50 -63 -184 -317 -121 -119 -191 -154
-66 50 9 -60 -70 -197 -272 -58 -2 -4 -92 46
Net Cash Flow 1 -2 -0 1 -1 13 15 4 -31 -0 7 70

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 32 31 55 58 54 43 52 56 79 83 81 90
Inventory Days 190 279 201 201 109 66 64 98 95 77 111 95
Days Payable 119 92 102 115 83 42 62 79 95 74 123 112
Cash Conversion Cycle 103 218 154 144 80 67 55 74 79 86 69 73
Working Capital Days -5 59 39 36 23 43 46 66 71 72 71 58
ROCE % 11% -3% 4% 12% 15% 56% 68% 54% 18% 14% 12% 9%

Shareholding Pattern

Numbers in percentages

13 Recently
Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
43.69% 48.19% 48.19% 48.19% 48.19% 48.19% 48.19% 48.19% 52.62% 52.62% 52.62% 52.62%
2.37% 2.43% 3.54% 2.33% 2.18% 1.40% 1.39% 1.63% 1.49% 1.47% 2.59% 2.25%
0.16% 0.23% 0.25% 0.35% 0.36% 0.29% 0.09% 0.07% 0.08% 0.07% 0.02% 0.05%
53.78% 49.15% 48.02% 49.12% 49.27% 50.11% 50.34% 50.11% 45.81% 45.84% 44.76% 45.10%
No. of Shareholders 1,43,3271,40,1771,26,0041,35,3971,34,2351,30,0031,28,6891,25,9791,26,7011,30,0021,25,0401,36,129

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls